Literature DB >> 10738048

Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.

T W Gress1, F J Nieto, E Shahar, M R Wofford, F L Brancati.   

Abstract

BACKGROUND: Previous research has suggested that thiazide diuretics and beta-blockers may promote the development of type 2 diabetes mellitus. However, the results of previous studies have been inconsistent, and many studies have been limited by inadequate data on outcomes and by potential confounding.
METHODS: We conducted a prospective study of 12,550 adults 45 to 64 years old who did not have diabetes. An extensive health evaluation conducted at base line included assessment of medication use and measurement of blood pressure with a random-zero sphygmomanometer. The incidence of new cases of diabetes was assessed after three years and after six years by measurement of serum glucose concentrations while the subjects were fasting.
RESULTS: After simultaneous adjustment for age, sex, race, education, adiposity, family history with respect to diabetes, physical-activity level, other health-related behavior, and coexisting illnesses, subjects with hypertension who were taking thiazide diuretics were not at greater risk for the subsequent development of diabetes than were subjects with hypertension who were not receiving any antihypertensive therapy (relative hazard, 0.91; 95 percent confidence interval, 0.73 to 1.13). Likewise, subjects who were taking angiotensin-converting-enzyme inhibitors and calcium-channel antagonists were not at greater risk than those not taking any medication. In contrast, subjects with hypertension who were taking beta-blockers had a 28 percent higher risk of subsequent diabetes (relative hazard, 1.28; 95 percent confidence interval, 1.04 to 1.57).
CONCLUSIONS: Concern about the risk of diabetes should not discourage physicians from prescribing thiazide diuretics to nondiabetic adults who have hypertension. The use of beta-blockers appears to increase the risk of diabetes, but this adverse effect must be weighed against the proven benefits of beta-blockers in reducing the risk of cardiovascular events.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10738048     DOI: 10.1056/NEJM200003303421301

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  248 in total

Review 1.  Beta-blockers in the management of hypertension in patients with type 2 diabetes mellitus: is there a role?

Authors:  F Dunne; M J Kendall; U Martin
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  The DASH trials implicate dysfunction in calcium regulation in the pathogenesis of human hypertension.

Authors:  A G Logan
Journal:  Curr Hypertens Rep       Date:  2001-10       Impact factor: 5.369

3.  Hypertension in diabetes mellitus: role of beta-blockers.

Authors:  F H Messerli; E Grossman
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 4.  Why beta-blockers are not cardioprotective in elderly patients with hypertension.

Authors:  Ehud Grossman; Franz H Messerli
Journal:  Curr Cardiol Rep       Date:  2002-11       Impact factor: 2.931

5.  Clinical trials report. Adverse prognostic significance of new diabetes in treated hypertensive subjects.

Authors:  Matthew R Weir
Journal:  Curr Hypertens Rep       Date:  2004-10       Impact factor: 5.369

Review 6.  Hypertension in the elderly.

Authors:  M Pestana
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

Review 7.  Angiotensin and insulin resistance: conspiracy theory.

Authors:  Raymond R Townsend
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

Review 8.  Cardiovascular risk factors in diabetic patients with hypertension.

Authors:  Nathaniel Winer; James R Sowers
Journal:  Curr Diab Rep       Date:  2002-06       Impact factor: 4.810

Review 9.  The choice of antihypertensive drugs in patients with diabetes: angiotensin II and beyond.

Authors:  Kambiz Kalantarinia; Helmy M Siragy
Journal:  Curr Diab Rep       Date:  2002-10       Impact factor: 4.810

Review 10.  Combating diabetic nephropathy with drug therapy.

Authors:  D Martins; K Norris
Journal:  Curr Diab Rep       Date:  2001-10       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.